Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

Docetaxel in Treating Patients With Solid Tumors

NCT00003565 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.

Interventions

  • DRUG docetaxel

Study Locations (20)

Illinois

  • MBCCOP - University of Illinois at Chicago — Chicago
  • Veterans Affairs Medical Center - Chicago (Westside Hospital) — Chicago
  • University of Chicago Cancer Research Center — Chicago
  • Louis A. Weiss Memorial Hospital — Chicago
  • West Suburban Center for Cancer Care — River Forest
  • Saint Anthony Medical Center — Rockford

Florida

  • Broward General Medical Center — Fort Lauderdale
  • Memorial Regional Hospital Comprehensive Cancer Center — Hollywood
  • CCOP - Mount Sinai Medical Center — Miami Beach
  • Florida Hospital Cancer Institute — Orlando
  • Helen and Harry Gray Cancer Institute at Good Samaritan Medical Center — West Palm Beach

California

  • Rebecca and John Moores UCSD Cancer Center — La Jolla
  • Veterans Affairs Medical Center - San Diego — San Diego
  • UCSF Comprehensive Cancer Center — San Francisco
  • Veterans Affairs Medical Center - San Francisco — San Francisco

District of Columbia

  • Lombardi Cancer Center — Washington D.C.
  • Walter Reed Army Medical Center — Washington D.C.
  • Veterans Affairs Medical Center - Washington, DC — Washington D.C.

Alabama

  • Northeast Alabama Regional Medical Center — Anniston

Delaware

  • CCOP - Christiana Care Health Services — Newark

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 1998-09
Est. Completion 2008-01
Phase Phase 2

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003565

The ClinicalTrials.gov registry entry for NCT00003565 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 147 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which docetaxel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00003565 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Illinois, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00003565 about?

NCT00003565 is a clinical study titled "Docetaxel in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.

What is the current status of trial NCT00003565?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 1998-09. Estimated completion is 2008-01.

What conditions does trial NCT00003565 study?

This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Head and Neck Cancer, Bladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00003565?

The interventions under investigation include: docetaxel (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00003565?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 147 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00003565 being conducted?

This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial